Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization.

@article{Topol2002MultiyearFO,
  title={Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization.},
  author={Eric J. Topol and Abraham Michael Lincoff and Dean J Kereiakes and Neal S. Kleiman and Eric A Cohen and James E. Ferguson and James E. Tcheng and Shelly K. Sapp and Robert M. Califf},
  journal={The American journal of medicine},
  year={2002},
  volume={113 1},
  pages={1-6}
}
There is considerable evidence supporting the use of platelet glycoprotein IIb/IIIa inhibitors to reduce ischemic complications of percutaneous coronary revascularization. However, long-term follow-up has been limited. In three large-scale randomized trials that tested abciximab at a uniform bolus dose and 12-hour infusion against placebo, in a double-blind fashion, a total of 5799 patients had their long-term follow-up vital status determined at a minimum of 7 years (EPIC), 4.5 years (EPILOG… CONTINUE READING